Press Releases MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
0.9642 ^USD	-1.61%		-0.59%	-9.88%

May. 22	MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	CI
May. 14	Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting	Jun. 05	GL
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	May. 22	GL
MiNK Reports First Quarter 2024 Results	May. 14	GL
MiNK Reports First Quarter 2024 Results	May. 14	AQ
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer	May. 13	GL
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer	May. 13	AQ
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report	Apr. 30	GL
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	Apr. 08	GL
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	Apr. 08	AQ
MiNK Reports Fourth Quarter and Year-End 2023 Results	Mar. 21	GL
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	Mar. 07	GL
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	Mar. 07	AQ
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	Mar. 06	GL
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	Mar. 06	AQ
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab	Feb. 14	GL
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	Feb. 06	GL
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	Feb. 06	AQ
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	Jan. 30	GL
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	Jan. 30	AQ
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development	Dec. 20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Press Releases

Filters